CTi Biopharma Corp

CTi Biopharma — Cell Therapeutics — Merger or Acquisition (March 2011)

7 slides from CTi Biopharma's merger presentation, Mar 14, 2011

  1. Slide 1: Tosedostat: Exclusive Marketing License and Co-Development Agreement

    Exhibit 99.3 Tosedostat Exclusive Marketing License and Co-Development Agreement

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this presentation include statements about future financial and ope

  3. Slide 3: Product/Deal Highlights

    Product/Deal Highlights Tosedostat: Novel tumor selective targeted therapy • Oral, once daily dosing, well tolerated Encouraging phase I/II data • 27% mono-therapy response rate elderly r/r AML, • Ongoing trials provide clinical news flow through 2012 Potentially rapid registration timeline: pivotal

  4. Slide 4: Tosedostat

    Tosedostat: Unlike current cytotoxic chemotherapy, Tosedostat does not interfere with genetic machinery of replicating cells • No hair loss, no damage to mouth and stomach lining, no depression of infection fighting white blood cells Tosedostat deprives cancer cells of the building blocks they need

  5. Slide 5: Summary Deal Terms & Structure

    Summary Deal Terms & Structure CTI gets exclusive development and marketing rights in the Americas; Chroma retains ROW Cost-sharing • CTI bears 75% of agreed-upon direct development expenses • Trials aimed at US/EU regulatory approval Development budget capped at $50mm over 3 years • 75% CTI - 25% C

  6. Slide 6: Market Opportunity: Current agents

    Market Opportunity: Current agents Indication WW 2010 Patent sales* expiration MDS $200MM 2013 MDS $534MM 2011 Ped. ALL $103MM 2018 VELCADE Multiple $1.5B 2017 Myeloma/Mantle Cell Multiple $2.5B 2019 Myeloma/Deletion 5q MDS *Information from SEC filings.

  7. Slide 7: Summary

    Summary Late-stage opportunity addressing significant unmet medical needs in large markets st • Potential 1 oral non-cytotoxic treatment for AML • Synergistic activity with “blockbuster” products (Velcade®, Dacogen®, Vidaza®, Revlimid®) in MDS, myeloma Diversifies CTI’s product portfolio with 3 pote

Cell Therapeutics — Merger or Acquisition (March 2011) on 6ix